Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

NCT06050707 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06050707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06050707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
September 29, 2023
Completion date
September 1, 2028
Enrollment
80 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma